Systemic lupus erythematosus (SLE) is a multisystemic autoimmunune disorder of unknown etiology. Many patients afflicted with SLE develop a severe nephritis mediated by the localization of immune complexes within glomeruli. Current treatments of this nephritis and other symptoms of the disease center on the use of steroids or cytotoxic immunosuppressive agents. While effective in some patients, these agents are non-specific and can cause serious side effects that often force discontinuation of treatment. We have identified a benzodiazepine (1) that does not bind to the central benzodiazepine receptor, which shows significant efficacy in treating the glomerulonephritis and other symptoms of disease in both (NZB x NZW)F1 and MRL/MpJ-lpr/lpr mice, the two most clinically relevant animal modes of human SLE. Both in vitro and in vivo experiments demonstrate that this benzodiazepine selectively induces apoptosis in lymphocytes directly responsible for autoimmune (B and T cell) mediated inflammation. At therapeutic doses, treatment suppresses the autoimmune response without altering normal immune function or evidence of side effects. Further development of 1 into a clinically useful agent requires a better understanding of both how this molecule induces cell death, and by what means apoptosis of lymphocytes results in disease improvement. To address this need, we propose to characterize the effects 1 has on cellular immune function by determining the phenotype of lymphoid cells killed by 1 in vivo and in vitro. Phenotypic analysis will be based on plasma membrane determinants and cytokine expression. Next, to uncover the mechanism by which 1 functions, we will identify the sub-cellular systems (e.g. caspases, mitochondria and other components of death response) triggered to execute 1-mediated cell death. Lastly, we will isolate the receptor of 1 based on yeast three-hybrid screening. If 1 is lethal to yeast, we will pursue an alternative strategy of mutagenesis followed by classical yeast genetics and functional cloning to generate resistant strains and identify molecules necessary for 1-induced death. The resistant strains developed will then serve as host strains for the three-hybrid system. These experiments will complement on-going efforts to identify the receptors(s) for 1 using more traditional affinity chromatography methods.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI047450-04
Application #
6632287
Study Section
Special Emphasis Panel (ZRG1-MCHA (02))
Program Officer
Johnson, David R
Project Start
2000-05-01
Project End
2004-06-30
Budget Start
2003-05-01
Budget End
2004-06-30
Support Year
4
Fiscal Year
2003
Total Cost
$226,500
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Franchi, Luigi; Monteleone, Ivan; Hao, Ling-Yang et al. (2017) Inhibiting Oxidative Phosphorylation In Vivo Restrains Th17 Effector Responses and Ameliorates Murine Colitis. J Immunol 198:2735-2746
Tkachev, Victor; Goodell, Stefanie; Opipari, Anthony W et al. (2015) Programmed death-1 controls T cell survival by regulating oxidative metabolism. J Immunol 194:5789-800
Hu, Xiao; Wang, Yahong; Hao, Ling-Yang et al. (2015) Sterol metabolism controls T(H)17 differentiation by generating endogenous ROR? agonists. Nat Chem Biol 11:141-7
Glick, Gary D; Rossignol, Rodrigue; Lyssiotis, Costas A et al. (2014) Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease. J Pharmacol Exp Ther 351:298-307
Wahl, Daniel R; Byersdorfer, Craig A; Ferrara, James L M et al. (2012) Distinct metabolic programs in activated T cells: opportunities for selective immunomodulation. Immunol Rev 249:104-15
Gatza, Erin; Wahl, Daniel R; Opipari, Anthony W et al. (2011) Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease. Sci Transl Med 3:67ra8
He, Shan; Kato, Koji; Jiang, Jiu et al. (2011) Characterization of the metabolic phenotype of rapamycin-treated CD8+ T cells with augmented ability to generate long-lasting memory cells. PLoS One 6:e20107
Wahl, D R; Petersen, B; Warner, R et al. (2010) Characterization of the metabolic phenotype of chronically activated lymphocytes. Lupus 19:1492-501
Stelzer, Andrew C; Frazee, Richard W; Van Huis, Chad et al. (2010) NMR studies of an immunomodulatory benzodiazepine binding to its molecular target on the mitochondrial F(1)F(0)-ATPase. Biopolymers 93:85-92
Blatt, Neal B; Boitano, Anthony E; Lyssiotis, Costas A et al. (2009) Bz-423 superoxide signals B cell apoptosis via Mcl-1, Bak, and Bax. Biochem Pharmacol 78:966-73

Showing the most recent 10 out of 17 publications